Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sangamo Therapeutics Inc.

www.sangamo.com

Latest From Sangamo Therapeutics Inc.

Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals

Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.

Commercial Exec Chat

Interview: Pfizer's Smith On Building A Gene Therapy Business

Pfizer entered the gene therapy space in 2014 and now has three programs in the clinic. Robert Smith, head of Pfizer’s gene therapy unit, spoke to Scrip about the company strategy, as well as the regulatory and reimbursement landscape.

Gene Therapy Strategy

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Financing Business Strategies

Roche Confident Spark Therapeutics Acquisition Will Complete In First Half

US financial regulators have not been quick at reviewing Roche’s multi-billion dollar acquisition of gene therapy biotech Spark Therapeutics, but it is still on track for completion in the first half of 2019.

 

Deals Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sangamo Therapeutics Inc.
  • Senior Management
  • Sandy Macrae, PhD, Pres. & CEO
    Kathy Yi, CFO
    Edward Conner, MD, SVP, CMO
  • Contact Info
  • Sangamo Therapeutics Inc.
    Phone: (510) 970-6000
    501 Canal Blvd.
    #A
    Richmond, CA 94804
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register